Table 3 Antibody-based therapy
Drug | Antigen target | Class | Patient population | N | ORR | CR | Grade 3 AE | Ref |
|---|---|---|---|---|---|---|---|---|
Blinatumomab | CD-19, CD-3 | Bispecific Ab | DLBCL, FL, MCL | 35 | 69 % 80% (FL) 71% (MCL) 55% (DLBCL) | 37% 40% (FL) 43% (MCL) 36% (DLBCL) | Leukopenia, neurologic event | [33] |
Blinatumomab | CD-19, CD-3 | Bispecific Ab | DLBCL | 25 | 36% | 16% | Leukopenia, thrombocytopenia, neurologic event | [34] |
CD20-Tcb (RG6026) | CD-20, CD-3 | Bispecific Ab | DLBCL,PMBCL, tFL, RT, FL | 64 | 38% | 24% | None | [35] |
Mosunetuzumab | CD-20, CD-3 | Bispecific Ab | DLBCL, tFL, FL | 98 | 41% | 27% | Anemia, neutropenia, hypophosphatemia | [36] |
Adct-402 (loncastuximab tesirine) | CD-19 | ADC | MCL, FL | 30 | 80% (FL) 46.7% (MCL) | 53.3% (FL) 26.7% (MCL) | Increased GGT, neutropenia, anemia | [37] |
Adct-301 (camidanlumab tesirine) | CD-25 | ADC | B cell NHL T cell NHL | 22 17 | 31.3% 50% | 18.8% 0% | Immune-related AE: dermatitis exfoliative, thyroiditis | [38] |
Adct-301 (camidanlumab tesirine) | CD-25 | ADC | HL | 60 | 38% | 24% | Increased GGT, ALT, AST, and ALP, maculopapular rash, anemia, and thrombocytopenia; immune-related AE: Guillain–Barré syndrome, thyroiditis | [39] |
MT 3724 | CD-20, Shiga-like toxin-I A1 | Recombinant fusion protein Ab | DLBCL | 24 | 12.5% | 4% | None | [40] |
Hu5F9-G4 | CD-47 | Ab | DLBCL, FL | 22 | 50% | 36% | Pulmonary embolism, ITP, anemia, thrombocytopenia, neutropenia, pyrexia, chills | [41] |
DCDS0780A | CD-79b | ADC | DLBCL, FL, MCL, MZL | 48 | 40% | 14% | Neutropenia, thrombocytopenia, hypercalcemia | [42] |
177 Lu-lilotomab satetraxetan | CD-37 | Antibody-radionuclide conjugate | FL, MCL, MZL, SLL | 74 | 61% | 26% | Neutropenia, thrombocytopenia, infections | [43] |